Abstract:Abstract Background Cystic Fibrosis (CF) is one of the most prevalent severe genetic diseases, with a high economic impact on healthcare systems due to its complexity. The life expectancy of CF patients has substantially lengthened due to early diagnosis and improvements in therapeutic regimens with Cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Therefore, strategies to ensure equitable access to these treatments should be optimized. Our study aimed to summarize existing literature regarding the costs of CF in Europe. Methods A systematic literature review was performed querying three online database (PubMed, Scopus, Web of Science) from January 2013 to March 2023. Studies carried out in European countries, written in English language, and focused on the socio-economic burden of CF were selected. Results Overall, 11 studies were considered. Across countries, the average total annual cost for a CF patient amounted to €14.174,00-53.256,00, higher for children (€15.771-60.412,00) compared to adults (€15.714-€47.217,00). The largest expenditures were recorded for annual direct healthcare costs, which amounted, per patient, to €9861,00-28.827,00, followed by direct non-healthcare costs (€4512,00-18.329,00). For adults, drugs, tests, and hospitalizations represented the primary cost drivers of direct healthcare costs, while for children, direct non-healthcare costs, especially for caregivers, were predominant. Moreover, indirect costs, whose main expenses were related to productivity loss and early retirement, ranged between €1,094-12,443 per patient per year. Conclusions The CF management is associated with relevant costs. CFTR modulators represent an important therapeutic opportunity of reducing the clinical and economic burden of CF. Therefore, new evidence and value-based economic evaluations, that also take into account a social perspective, are needed to support the decision-making process. Key messages • The use of new health economic models is needed to guide the policy-makers in a value-based evaluation of Cystic Fibrosis treatments that take into account their whole value. • The assessment of the socio-economic burden of Cystic Fibrosis could guide the identification of the main actions to be implemented to respond adequately to the real health needs of patients.

Expanding the Impact of New Cystic Fibrosis Therapies in Low‐ and Middle‐Income Countries

International disparities in diagnosis and treatment access for cystic fibrosis

Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!

Challenges in the care of cystic fibrosis in low‐to‐middle income countries

The future of cystic fibrosis: A global perspective

New drugs, new challenges in cystic fibrosis care

Identifying disparities in pediatric cystic fibrosis care between low-middle and middle-high income countries in the Middle East

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Socio-economic burden of cystic fibrosis in Europe: a systematic review of cost of illness evidence

Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Until it's done for everyone: the role of CFTR modulator label expansion

Implications for the Microbial Landscape in Cystic Fibrosis

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles

Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind

Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations

Disparities in outcomes by race and ethnicity in the Canadian cystic fibrosis population

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

Advances in the Cystic Fibrosis Drug Development Pipeline

Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?